New antibiotics for complicated urinary tract infections
Official title: Development of oxepanoprolinamide antibiotics for the treatment of complicated urinary tract infections.
Funded at Kinvard Bio, INC. · NIH-11313278 · Data updated 2026-11-12
A new class of powerful antibiotics called oxepanoprolinamides is being developed to treat complicated urinary tract infections, especially when usual medicines fail.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kinvard Bio, INC. NIH-funded |
| Lab location | 1 site (Flourtown, United States) |
| Project start | August 3, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $314,363 |
| NIH project number | 1R43AI197431-01 |
| Project ID | NIH-11313278 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with complicated urinary tract infections who need outpatient or step-down therapy from intravenous to oral treatment.
✕Less likely to help
People whose infections are not caused by the targeted Gram-negative bacteria or who cannot take the study drugs due to safety concerns may not benefit.
What this research studies
This project aims to create a non-carbapenem, non-BL/BLI intravenous antibiotic with an oral step-down option to treat complicated urinary tract infections. It focuses on improving how well these drugs bind to the bacterial ribosome to fight Gram-negative pathogens. The work is at the preclinical/early development stage and is designed to enable outpatient treatment and earlier hospital discharge. If successful, it could reduce reliance on last-line antibiotics and expand treatment options for people with cUTIs.
Why it matters
Potential benefit: If successful, patients with cUTIs could receive effective treatments fewer side effects and have shorter hospital stays.
How similar studies have gone: This approach is building on the known lincosamide framework with enhanced Gram-negative activity, showing potential but requires clinical validation.
Where this research is happening
-
Kinvard Bio, INC.
Flourtown, United States Active
Researchers
- Principal investigator: Wu, Jun Yu Kelvin — Kinvard Bio, INC.
- Study coordinator: Wu, Jun Yu Kelvin
Related research
Other NIH-funded projects on the same topics.
-
New ways to stop urinary tract infections by blocking bacterial adhesion
A study to test new methods that prevent bacteria from sticking to urinary tract tissues and devices, potentially stopping infections before they start.
-
Hybridization capture sequencing to quickly identify canine urinary pathogens and resistance genes
A new sequencing approach directly from dog urine aims to rapidly identify bacteria causing urinary infections and their drug-resistance profiles to guide treatment.
-
Enterococcal Proteases and CAUTI: How the body’s environment activates bacteria to cause infections
A small grant is exploring how two enzymes from Enterococcus faecalis interact with the urine environment to drive catheter-associated urinary tract infections and why these infections are hard to treat.
-
Daily nitrofurantoin with or without bladder cauterization to prevent recurrent bladder infections in women
This study tests two approaches to prevent recurrent bladder infections in women: taking a low-dose antibiotic every day versus adding a bladder cauterization procedure plus the same daily antibiotic.
-
New bacterial pathway that helps cause bladder infections
Researchers are exploring how bacteria steal nutrients in the bladder and how the body fights them to help people with urinary tract infections.
-
New oral antifungal for tough Candida UTIs
A Johns Hopkins team is testing a new oral antifungal medicine called fungerps to treat urinary tract infections caused by azole-resistant Candida fungi.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.